%0 Journal Article
%T Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism
%A Gerard Aragon¨¨s
%A Carlos Alonso-Villaverde
%A Pedro Pardo-Reche
%A Anna Rull
%A Ra¨²l Beltr¨¢n-Deb¨®n
%A Esther Rodr¨ªguez-Gallego
%A Laura Fern¨¢ndez-Sender
%A Jordi Camps
%A Jorge Joven
%J BMC Medical Genetics
%D 2011
%I BioMed Central
%R 10.1186/1471-2350-12-120
%X We determined the rs10892151 genotype distribution and serum apolipoprotein (apo) C-III concentration in a group of HIV-infected patients (n = 208) and in a group of age and sex-matched healthy volunteers (n = 200). Circulating lipid and lipoprotein levels were followed for 12 months after antiretroviral treatment initiation in the HIV-infected group.There were no significant variations in the frequency of the A allele between the healthy and HIV-infected groups (7.5 vs. 8.6%, respectively; p = 0.7); additionally, the A allele was not related to serum apo C-III concentration. However, among patients receiving protease inhibitor (PI) treatment, carriers of the A allele had significantly increased serum triglyceride (5.76 ¡À 2.54 mmol/L) and total cholesterol (6.63 ¡À 2.85 mmol/L) concentrations together with depressed levels of HDL-cholesterol (0.75 ¡À 0.3 mmol/L) when compared with patients not carrying the allele (2.43 ¡À 1.32, 5.2 ¡À 2.17 and 1.24 ¡À 0.4 mmol/L, respectively) at the end of the study. This effect was only evident for HDL-cholesterol concentration when patients were treated with non-nucleoside reverse transcriptase inhibitors (1.05 ¡À 0.4 vs. 1.28 ¡À 0.4 mmol/L).The A allelic variant of the rs10892151 polymorphism is not associated with serum apo C-III concentration, but predisposes HIV-infected patients to less favorable lipid profile, particularly in those patients treated with PIs.The introduction of antiretroviral therapies has led to a remarkable increase in the life expectancy of patients with human immunodeficiency virus (HIV) infection. Unfortunately, current treatment may cause a wide spectrum of metabolic disturbances and comorbid conditions, with cardiovascular disease as an important example [1]. Dyslipidemia is particularly frequent and is mostly characterized by hypertriglyceridemia and low HDL-cholesterol concentrations. Although this phenomenon has been attributed, at least in part, to the use of protease inhibitors (i.e., ritonavir or riton
%U http://www.biomedcentral.com/1471-2350/12/120